ARA-290 (Cibinetide) Research Overview

ARA-290, also known by its INN cibinetide, is a synthetic 11-amino-acid peptide engineered from the tertiary structure of erythropoietin (EPO). Unlike native EPO, which drives red blood cell production, ARA-290 was deliberately designed to retain only EPO's tissue-protective and anti-inflammatory signaling while eliminating erythropoietic activity entirely. It represents a class of compounds sometimes called non-erythropoietic EPO-mimetics. Investigational human trials have focused on neuropathic pain associated with sarcoidosis-related small fiber neuropathy, where early results showed both symptom improvement and potential nerve fiber regeneration.

What Is ARA-290?

ARA-290 is composed of 11 amino acids that correspond to the aqueous-facing surface of helix B (residues 58–82) of the EPO protein. This region of EPO was identified by Brines and colleagues as the domain responsible for tissue-protective effects, spatially distinct from the receptor binding domain responsible for erythropoiesis. By isolating this fragment, the researchers eliminated the thromboembolic and hematologic risks associated with pharmacological EPO administration.

ARA-290 was developed by Araim Pharmaceuticals and has received FDA Orphan Drug Designation for neuropathic pain in sarcoidosis. It has not received FDA or EMA approval for any indication and remains investigational.

Mechanism of Action

ARA-290 selectively binds to the innate repair receptor (IRR), a heteromeric complex formed by the erythropoietin receptor (EPOR) and the beta-common receptor (βcR). This receptor complex is constitutively expressed at low levels in healthy tissue but is markedly upregulated in injured, hypoxic, or inflamed tissue. Because IRR expression is enriched at sites of damage, ARA-290 has a degree of tissue-selective targeting.

Binding to IRR activates anti-apoptotic signaling cascades including PI3K/Akt and NF-κB-suppressive pathways, reduces pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6), and appears to support peripheral nerve fiber survival and regeneration. In small fiber neuropathy, where unmyelinated C-fibers and thin A-delta fibers are selectively damaged, this mechanism may offer a targeted repair pathway.

Critically, ARA-290 does not activate the classical EPOR homodimer responsible for erythropoiesis. In preclinical models and in human trials, no increase in hemoglobin, hematocrit, or erythrocyte count has been observed, distinguishing it clearly from therapeutic EPO.

What the Research Shows

Brines et al. (2008) published the foundational paper in PNAS establishing that 11-amino-acid peptides derived from the aqueous face of EPO’s helix B are neuroprotective in rodent models of ischemic stroke and peripheral nerve trauma, and that these peptides produce no erythropoietic effect in vivo (PMID 18676614, PNAS 2008). This work directly established the scientific rationale for ARA-290.

Brines et al. (2014) conducted the first randomized, double-blind, placebo-controlled human trial of ARA-290 in sarcoidosis. Twenty-two patients with sarcoidosis and symptoms of small fiber neuropathy (SFN) received intravenous ARA-290 2 mg or placebo three times weekly for four weeks. The treated group showed significant improvements in neuropathic pain scores and quality-of-life measures relative to placebo. No serious adverse events attributable to ARA-290 were reported.

Schmidt et al. (2015) examined corneal nerve fiber density — a validated surrogate marker for small fiber neuropathy — in sarcoidosis patients treated with cibinetide. Treated patients showed improvement in corneal nerve fiber abundance as measured by confocal corneal microscopy, suggesting a structural — not merely symptomatic — effect. This is a meaningful finding because objective regeneration of intraepidermal nerve fibers is difficult to demonstrate with most analgesic interventions.

These are the key human data points. The trials were small (n=22 in the pivotal Phase 2), open to confounding from sarcoidosis disease heterogeneity, and have not been replicated in larger Phase 3 studies. ARA-290 has not demonstrated efficacy in any completed large-scale registration trial. The mixed and preliminary nature of the evidence should be acknowledged explicitly.

Pharmacokinetics

In human trials, ARA-290 has been administered intravenously at 2 mg doses. As an 11-amino-acid peptide, ARA-290 is expected to be rapidly cleared from circulation by endopeptidases and renal filtration. No published PK data for subcutaneous or intranasal routes in humans is available from peer-reviewed sources at the time of writing. Oral bioavailability is expected to be negligible due to gastrointestinal proteolysis.

Reported Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Human trials of ARA-290 have used intravenous doses of 2 mg administered three times weekly for four weeks. This is the only dosing regimen with published human safety and tolerability data. No dose-ranging study for subcutaneous or alternative routes in humans appears in the peer-reviewed literature reviewed here. All dose information reflects investigational research protocols under physician supervision in controlled trial settings.

Storage and Handling

As a short lyophilized peptide, ARA-290 should be stored at -20 °C in its lyophilized state and protected from light and moisture. After reconstitution in sterile or bacteriostatic water, solutions should be refrigerated at 2–8 °C and used within 28 days. Freeze-thaw cycling should be avoided as it can degrade peptide integrity. All preparation and handling should take place in a sterile research laboratory environment.

What ARA-290 Is NOT

ARA-290 is not erythropoietin and does not stimulate red blood cell production. It is not an approved drug for neuropathic pain, sarcoidosis, or any other indication. It is not a performance-enhancing agent for athletic purposes — the absence of erythropoietic effect specifically means it would not increase oxygen-carrying capacity. It is distinct from BPC-157 and other healing-associated research peptides in both origin and mechanism. Phase 2 data showing benefit in small fiber neuropathy is preliminary and does not establish proof of efficacy.

References

1. Brines M et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. PNAS. 2008;105(31):10925–10930. PMID 18676614.

2. Brines M et al. ARA 290, a nonerythropoietic peptide engineered from the EPO helix B surface, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2014;20:658–666. PMC4365069.

3. Schmidt P et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2015.

4. Brines M et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18:1568. PMC3563705.